MANIFESTAZIONI EXTRAINTESTINALI DELLE IBD: LE NUOVE LINEE GUIDA 2024 “ECCO”. DA “JCC” (FREE)

GASTROENTEROLOGIA, IBD, LINEE GUIDA EBM, NEWSLETTER, Senza categoria

ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease  Hannah Gordon et al. 1. Introduction This is the second European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on extraintestinal manifestations [EIMs] of inflammatory bowel disease [IBD] and anaemia.1 Up to 50% of patients with IBD will develop at least one EIM, which may impact each body…

“WALLED-OFF NECROSIS” DEL PANCREAS. METAL VS PLASTIC STENTS SONO COMPARABILI. UNA BUONA META-ANALISI DAGLI USA. DA”ENDOSCOPY”

CHIRURGIA, ECOGRAFIA ED ECOENDOSCOPIA, ENDOSCOPIA, GASTROENTEROLOGIA, NEWSLETTER, PANCREAS E VIE BILIARI, Senza categoria

Treatment of walled-off necrosis using lumen-apposing metal stents versus plastic stents: a systematic review and meta-analysis of data from randomized trials JYoung Bang et al. Abstract Background: Walled-off necrosis (WON) is highly morbid disease most effectively managed by endoscopic drainage with lumen-apposing metal stents (LAMSs) or plastic stents, with or without necrosectomy. This meta-analysis compared…

COLITE ULCEROSA ACUTA SEVERA : AGGIUNGETE TOFACITINIB ALLO STEROIDE ! UN IMPORTANTE TRIAL MONOCENTRICO DA “AMERICAN JOURNAL OF GASTROENTEROLOGY”

CHIRURGIA, GASTROENTEROLOGIA, IBD, NEWSLETTER, Senza categoria

Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial Arshdeep Singh et al. Abstract Introduction: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%-40% of the patients are refractory to corticosteroids. We investigated whether addition of tofacitinib to corticosteroids improved the treatment responsiveness in patients…

COLNGITE PRIMARIA BILIARE: UN ALTRO PPRA (dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist) IN SECONDA LINEA, ELAFIBRANOR. UN TRIAL MULTICENTRICO DA”THE NEW ENGLAND JOURNAL OF MEDICINE”

EPATOLOGIA, GASTROENTEROLOGIA, NEWSLETTER, Senza categoria

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis Kris V. Kowdley et al. Abstract BACKGROUND Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have…

GLI AGONISTI PPAR NELLA COLANGITE PRIMARIA BILIARE. UN GRANDE EDITORIALE 2024 DAL “NEW ENGLAND JOURNAL OF MEDICINE”

EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

PPAR Agonists in Primary Biliary Cholangitis Bernd Schnabl, M.D. Kowdley et al.1 and Hirschfield et al.2 now report in the Journal the results of trials of elafibranor and seladelpar, respectively, for the treatment of primary biliary cholangitis, a chronic liver disease that affects the bile ducts. Both drugs are peroxisome proliferator–activated receptor (PPAR) agonists, and the results support their…

INFLIXIMAB PER IL MANTENIMENTO DELLA REMISSIONE NEL CROHN. L’ULTIMA REVISIONE 2024 DALLA “COCHRANE LIBRARY” (FREE)

GASTROENTEROLOGIA, IBD, NEWSLETTER, Senza categoria

Infliximab for maintenance of medically-induced remission in Crohn’s disease (Review) Gordon M, Sinopoulou et al. Background Infliximab is a monoclonal antibody that binds and neutralises tumour necrosis factor-alpha (TNF-α) which is present in high levels in the blood serum, mucosa and stool of patients with Crohn’s disease. Objectives To determine the efficacy and safety of…